VORICONAZOLE

PeakSM

voriconazole

NDAINTRAVENOUSPOWDER
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Cytochrome P450 3A4 Inhibitors

Pharmacologic Class:

Azole Antifungal

Clinical Trials (5)

NCT06493409Phase 1Completed

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

Started Aug 2024
32 enrolled
Healthy Volunteers
NCT03672292Phase 2Terminated

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

Started Jan 2019
NCT03515382Phase 1Completed

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Started Mar 2018
18 enrolled
Healthy
NCT02283905Phase 4Terminated

Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

Started Jun 2015
2 enrolled
Blastomycosis
NCT02074462N/ACompleted

Effect of Inflammation on Voriconazole Concentration

Started Jan 2014
36 enrolled
InflammationFungal Infection